Conventional imaging of prostate cancer includes ultrasound examinations of the prostate and bone scans. These imaging methods have many shortcomings. Radiolabelled choline PET/CT scan is widely used in Europe for patients with a PSA-recurrence.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The scan may identify the site of the recurrence and help urologist to decide whether the patients have a loco-regional recurrence or a recurrence in distant organs. In a previous systematic review and meta-analysis we found that the choline PET/CT scan was better than a bone scan to detect to site for the recurrence (1). Therefore this new review reported outcome with use of non-choline tracers for the PET/CT scans and their role to guide radiotherapy of loco-regional prostate cancer (2). We found that both 11C-Acetate and 18F-FACBC were useful tracers as alternatives to radiolabelled choline. In addition recent studies found promising results with a PSMA-ligand tracer (3). This new tracer gave PET/CT possibility to detect the site of recurrence for more than half of the patients with a PSA recurrence in the range of 0.2 to 1.0 ng/ml. Therefore the new tracer is more sensitive for detection of recurrent prostate cancer than PET/CT with radiolabelled choline. Functional imaging has an increasing role for the management of patients with a PSA-recurrence. Functional imaging may help to diagnose a relevant target and optimize treatment. Conventional radiotherapy for patients with PSA-recurrent prostate cancer without use of functional imaging may imply a unnecessary risk for treatment of irrelevant sites.
*The author welcomes collaboration with interested institutions. Email Dr. von Eyben via the link above for more information.
1. von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun. 2014;35:221-30.
2. von Eyben FE, Kairemo K, Kiljunen T, Joensuu T. Planning of External Beam Radiotherapy for Prostate Cancer Guided by PET/CT. Curr Radiopharm. 2015;8:19-31.
3. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.